**Revenue distribution by sector:**
- Animal health: 100%

**TOP 3 markets and their percentage shares:**
- Europe: 45%
- North America: 35%
- Asia-Pacific: 15%

Vetoquinol SA is a company that is fully specialized in animal health. Therefore, the revenues come from the development, production, and distribution of veterinary drugs and health products for pets and livestock.

The European market is the largest revenue generator for Vetoquinol, followed by North America, which also has a significant share of the company's total revenue. The Asia-Pacific region shows a growing interest in animal health products, which is reflected in an increasing share of revenue.

**Production sites of Vetoquinol SA:**

1. **France**
2. **Canada**
3. **Poland**

Vetoquinol SA is an internationally operating company specializing in the production of animal health products. The main production sites are located in France, Canada, and Poland. These locations enable the company to efficiently distribute its products in various markets and optimize the supply chain. The strategic placement of the production sites also supports the company's flexibility and adaptability to regional market requirements.

**Revenue Growth:** 8.5% (2025)

**Profit Growth:** 7.2% (2025)

Vetoquinol SA pursues a growth strategy based on three main pillars: innovation, geographical expansion, and strategic acquisitions.

The company continuously invests in research and development to develop innovative animal health products and health solutions. This includes both new products and improving existing formulations to meet the changing needs of the market.

Geographically, Vetoquinol aims to expand into high-growth markets, particularly in Asia and Latin America. These regions offer significant growth opportunities due to the increasing demand for animal health products.

Additionally, Vetoquinol focuses on strategic acquisitions to expand its product portfolio and strengthen its market presence. These acquisitions are aimed at creating synergies and improving operational efficiency.

**Main raw materials:** Pharmaceutical active ingredients, excipients, packaging materials
**Countries of origin:** China, India, Germany, France

Vetoquinol SA mainly imports pharmaceutical active ingredients and excipients needed for the production of their veterinary medicines. These raw materials mainly come from China and India, which are considered the main suppliers of pharmaceutical basic substances.

In addition, the company sources packaging materials from European countries, especially from Germany and France, to ensure the quality and sustainability of their products. The choice of these countries is based on their advanced technologies and proximity to Vetoquinol's production facilities in Europe.

**Market Share:** 5% in the animal health industry (estimated 2026)
**R&D Expenses:** 8% of revenue (2025)
**EBITDA Margin:** 18% (2025)

Vetoquinol SA has a moderate competitive advantage in the animal health industry. The company benefits from a solid market position with an estimated market share of 5%, indicating a strong presence in Europe and a growing presence in North America.

The continuous investment in research and development, accounting for approximately 8% of revenue, enables Vetoquinol to develop innovative products and differentiate itself from competitors. These investments help the company to respond to new market trends and customer needs.

The EBITDA margin of 18% demonstrates an efficient cost structure and the ability to operate profitably. This margin is competitive compared to some competitors in the industry, indicating good operational efficiency and cost control.

Overall, Vetoquinol SA's competitive advantage is supported by its R&D investments, market position, and operational efficiency, even though the market share is limited compared to larger competitors.

**Institutional Investor Share:** Estimated at around 30% (2026)

**Insider Buys/Sells:** No significant transactions in the last 12 months (2026)

The institutional investor share in Vetoquinol SA is approximately 30%, which is typical for a company of this size and industry. Institutional investors appreciate the stability and growth potential of the company.

There have been no significant insider transactions in the last 12 months, indicating that the management has confidence in the current company strategy and market development. This can be seen as a positive signal for investors, as it suggests stable corporate leadership.

**Market share of Vetoquinol SA:** Estimated 5% (2026)

**Top competitors and their market shares:**
1. Zoetis Inc. - 25%
2. Elanco Animal Health - 20%
3. Merck Animal Health - 15%
4. Boehringer Ingelheim Animal Health - 10%
5. Bayer Animal Health - 8%
6. Vetoquinol SA - 5%
7. Virbac - 4%
8. Ceva Santé Animale - 3%
9. Dechra Pharmaceuticals - 2%
10. Phibro Animal Health - 1%

Vetoquinol SA is a medium-sized player in the global animal health market. The market share of approximately 5% indicates that the company lags behind the leading companies such as Zoetis and Elanco, which have significantly larger market shares.

Vetoquinol SA's moat mainly lies in its specialization in specific niche products and its strong presence in Europe. Compared to larger competitors that have a broader product range and a stronger global presence, Vetoquinol's moat is less pronounced. The leading companies have more extensive research and development resources, giving them an advantage in innovating new products.

Overall, Vetoquinol SA has a certain competitive advantage in specific segments, but larger competitors are in a stronger position to benefit long-term from economies of scale and innovations due to their resources and market presence.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 7.2% (2025)
**R&D Expenses:** 9.3% of revenue (2025)

Vetoquinol SA recorded solid revenue growth of 8.5% in 2025, driven by strong demand for its animal health products. The 7.2% profit growth indicates that the company was able to effectively manage its costs and increase profitability.

Another positive aspect is the high proportion of research and development as a percentage of revenue, which stands at 9.3%. This suggests that Vetoquinol SA is investing in innovations to expand its product range and remain competitive.

In summary, Vetoquinol SA appears to be a potentially good investment due to its solid growth and strategic investments in R&D. However, investors should also consider other factors such as market trends and competition before making a decision.

**Dividend Yield:** 1.5% (2026, estimated)
**Dividend History:** Continuous payout over the last 5 years

Vetoquinol SA has distributed a dividend in recent years, with the dividend yield estimated to be around 1.5% for 2026. The company has a history of continuous dividend payments, indicating a certain level of reliability.

The stability of the payout is supported by the solid financial performance and conservative payout policy of the company. Vetoquinol SA operates in the animal health industry, which is considered relatively stable, also contributing to the reliability of dividend payments.